🔗 Share this article

Given that America continues making unprecedented revisions to its vaccination recommendations, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations throughout the global health crisis and has focused upon alleged deaths after COVID-19 vaccination in her recent time at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Agency leaders planned to announce radical revisions to the childhood vaccination calendar recently, bringing the US with the Danish national calendar, it is understood – a major change that would put the US out of alignment with much of the international standard with no evidence for benefit. The planned update has been pushed back until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to run the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some childhood immunization guidelines in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a population about the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

The appointee has no apparent experience in drug development, approval processes or leadership, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “understand regulatory frameworks and the science of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner emphasized.

“Many people just zeroes in on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be managed,” she explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial leadership aspect to the job, which supervises in excess of 5,000 employees. “It is a huge administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Programs

In response to concerns about Dr. Høeg's qualifications and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a spokesperson said that the “concerns stem from incorrect assumptions”.

“This background matches the responsibilities of her role,” the representative explained, noting the period Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid drug-approval program that reportedly concerned her preceding directors. “By what process are these therapies being selected for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, with the exception of shots.”

Public History on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, track record, some experts said. She published a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are riskier than they are.

Included in her “policy goals” for the new administration included altering guidelines for novel immunizations and halting “unnecessary” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of preventing adolescent males from getting Covid vaccines.

“She is an complete dogmatist who begins with her beliefs and works backwards to retrofit the science in a very deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|